Canadian Society of Internal Medicine, 2002 National Conference, Oct. 16 to 20, 2002, Halifax, NS. Hosted by the Atlantic Regional CME

October 2002
Clinical & Investigative Medicine;Oct2002, Vol. 25 Issue 5, p195
Academic Journal
Presents abstracts of studies related to medicine, presented at the 2002 Canadian Society of Internal Medicine conference on October 16-20, 2002. 'Malignancy Associated With Thrombosis in Heparin-Induced Thrombocytopenia,' by L.V. Opatrny and M. Warner; 'McMaster Stroke Management Study,' by A. Gangji, F. Al Shehri and T. Woo; 'Anticoagulation of Atrial Fibrillation in Patients With Ventricular Pacemakers,' by P. Leong-Sit and M. Ahmad.


Related Articles

  • Antithrombotic treatment in atrial fibrillation. Lip, G. Y. H.; Boos, C. J. // Postgraduate Medical Journal;May2008, Vol. 84 Issue 991, p252 

    Atrial fibrillation (AF) can significantly increase morbidity and mortality. It is gaining in clinical and economic importance, being the most commonly encountered tachyarrhythmia in clinical practice. Stroke is the most serious complication. Evidence from AF antithrombotic treatment trials is...

  • Initiation of Oral Anticoagulation after Acute Ischaemic Stroke or Transient Ischaemic Attack: Timing and Complications of Overlapping Heparin or Conventional Treatment. Audebert, Heinrich J.; Schenk, Berit; Tietz, Viola; Schenkel, Johannes; Heuschmann, Peter U. // Cerebrovascular Diseases;Aug2008, Vol. 26 Issue 2, p171 

    Background: Oral anticoagulation is highly effective for secondary prevention of cardioembolic strokes in patients with atrial fibrillation (AF). There are no studies investigating timing and complications of different strategies for initiation of oral anticoagulation after acute stroke or...

  • Anticoagulants: increased risk of stroke and haemorrhage in females.  // Reactions Weekly;10/22/2005, Issue 1074, p5 

    Reports on the results of a study on the comparison of the risk of stroke between females and males receiving anticoagulants for atrial fibrillation (AF) presented at the Annual Congress of the European Society of Cardiology in Stockholm, Sweden in 2005. Number of patients who were involved in...

  • Long-Term Outcome after Stroke due to Atrial Fibrillation. H.P. Mattle // Cerebrovascular Diseases;Apr2003 Supplement 1, Vol. 16, p3 

    AbstractAtrial fibrillation (AF) is the most common cardiac arrhythmia. AF is paroxysmal or persistent and becomes permanent when it does not convert to sinus rhythm spontaneously or when attempted cardioversion fails. The prevalence of AF is 0.4% in the general population and increases with age...

  • Welcher Patient mit chronischem Vorhofflimmern kommt in Frage für einen perkutanen Vorhofohrverschluss? Wagdi, P.; Ritter, M.; Salzer, F. // Praxis (16618157);3/16/2011, Vol. 100 Issue 6, p357 

    No abstract available.

  • Fibrilhação Auricular na Doença Cerebrovascular: A Perspectiva Neurológica Nacional. SARGENTO-FREITAS, João; SILVA, Fernando; KOEHLER, Sebastian; ISIDORO, Luís; MENDONÇA, Nuno; MACHADO, Cristina; CORDEIRO, Gustavo; CUNHA, Luís // Acta Medica Portuguesa;Mar/Apr2013, Vol. 26 Issue 2, p86 

    Background: Cardioembolism due to atrial fibrillation assumes a dominant etiologic role in cerebrovascular diseases due to its growing incidence, high embolic risk and particular aspects of clinical events caused. Our objectives are to analyze the frequency of atrial fibrillation in patients...

  • Rivaroxaban: Another Warfarin Replacement.  // Critical Care Alert;Jan2010 Pharmacology, p1 

    The article presents research on rivaroxaban as a replacement for warfarin, wherein the results showed that rivaroxaban requires no monitoring and has the advantage of being dosed once a day.

  • Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Hart, Robert G.; Halperin, Jonathan L.; Pearce, Lesly A.; Anderson, David C.; Kronmal, Richard A.; McBride, Ruth; Nasco, Elaine; Sherman, David G.; Talbert, Robert L.; Marler, John R. // Annals of Internal Medicine;5/20/2003, Vol. 138 Issue 10, p831 

    Atrial fibrillation predisposes to left atrial thrombus formation and carries a sixfold increased risk for stroke. Antithrombotic therapies are the mainstay for stroke prevention. The National Institute of Neurological Disorders and Stroke-sponsored Stroke Prevention in Atrial Fibrillation...

  • Antithrombotic treatment and atrial fibrillation: Warfarin reduces the risk of first time strokes by two thirds. Lowe, Gordon D.O. // BMJ: British Medical Journal (International Edition);12/12/92, Vol. 305 Issue 6867, p1445 

    Examines the use of antithrombotic treatment in preventing ischemic stroke in patients with atrial fibrillation. Association of atrial fibrillation with the mortality of patients; Application of warfarin as a prevention of stroke ; Efficacy of warfarin.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics